Weight management does not follow one universal formula, and the most effective plan respects your health history, goals, preferences, and response to treatment. A 2026 systematic review compared endoscopic sleeve gastroplasty, or ESG, alone with ESG plus anti-obesity medication, offering a useful perspective for anyone exploring a personalized, medically supervised path forward. The team at Endoslim Clinic of Atlantic Gastroenterology in Brooklyn, New York, is here to let you know about seven things you should know about medication and weight loss paired with the ESG procedure.
1. ESG reshapes the stomach without traditional surgery.
During the ESG procedure for weight loss, a gastroenterologist uses an endoscope passed through the mouth and places sutures inside the stomach, creating a smaller, tube-like shape that supports earlier fullness and smaller portions. Because the doctor makes no abdominal incisions, ESG offers a minimally invasive approach, although it still requires thoughtful preparation, recovery guidance, and ongoing follow-up.
2. Weight loss medications work through different pathways.
Anti-obesity medications support weight management by influencing appetite, fullness, food intake, or related metabolic processes, depending on the specific drug. The reviewed studies included several options, such as semaglutide, liraglutide, tirzepatide, topiramate, and others, which means the results do not describe one identical medication plan for every patient.
3. Combining treatments showed a possible early advantage.
Across ten studies involving 578 participants, people who received ESG plus medication showed a modest average advantage of about 1.9 percentage points in total weight loss at approximately seven months. However, this difference did not actually reach statistical significance, so the findings suggest a promising early signal rather than proof that combination treatment always produces better results.
4. More treatment does not automatically mean better treatment.
The review found no consistent long-term weight-loss advantage for ESG plus medication over ESG alone, and the combined approach also produced no meaningful overall improvement in HbA1c compared with ESG by itself. A well-matched strategy matters more than simply adding another therapy, especially when cost, side effects, medication tolerance, and treatment burden are part of the conversation.
5. Timing and medication choice shape the experience.
Some patients start medication alongside ESG, while others add it later when progress slows or weight regain develops, and these different approaches contributed to wide variation among the studies. Your gastroenterologist evaluates your previous efforts, metabolic health, appetite patterns, response to treatment, and personal goals before recommending when medication fits into the plan.
6. Long-term support remains part of every option.
ESG and medication serve as tools within comprehensive obesity care rather than replacements for nutrition, movement, sleep, behavior change, and regular medical monitoring. Consistent follow-up helps your care team assess progress, manage side effects, adjust treatment, and protect the results you worked hard to achieve.
7. Personalized care is the clearest lesson.
The researchers concluded that combination therapy deserves selective use instead of routine use for everyone, partly because only three of the ten included studies were full-text publications and the evidence varied considerably. When considering medication and weight loss in Brooklyn, New York, an individualized consultation provides far more value than assuming that the newest or most intensive option automatically fits your body and life.
